When a single pivotal trial should not be enough-the case of drotrecogin-alfa (activated).
Wiedermann
Christian J
CJ
D002986:Clinical Trials as Topic; D017277:Drug Approval; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D011486:Protein C / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated